CN116650611B - 一种治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条 - Google Patents
一种治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条 Download PDFInfo
- Publication number
- CN116650611B CN116650611B CN202310496722.XA CN202310496722A CN116650611B CN 116650611 B CN116650611 B CN 116650611B CN 202310496722 A CN202310496722 A CN 202310496722A CN 116650611 B CN116650611 B CN 116650611B
- Authority
- CN
- China
- Prior art keywords
- moxa
- traditional chinese
- chinese medicine
- paper
- columnar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010013935 Dysmenorrhoea Diseases 0.000 title claims abstract description 59
- 238000005345 coagulation Methods 0.000 title claims abstract description 26
- 230000015271 coagulation Effects 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 97
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 230000000202 analgesic effect Effects 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 241000218176 Corydalis Species 0.000 claims abstract description 9
- 241000628997 Flos Species 0.000 claims abstract description 9
- 244000178870 Lavandula angustifolia Species 0.000 claims abstract description 9
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims abstract description 9
- 239000001102 lavandula vera Substances 0.000 claims abstract description 9
- 235000018219 lavender Nutrition 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 238000010298 pulverizing process Methods 0.000 claims abstract description 9
- 239000002023 wood Substances 0.000 claims abstract description 9
- 240000000249 Morus alba Species 0.000 claims description 14
- 235000008708 Morus alba Nutrition 0.000 claims description 14
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 8
- 102000002322 Egg Proteins Human genes 0.000 claims description 8
- 108010000912 Egg Proteins Proteins 0.000 claims description 8
- 235000014103 egg white Nutrition 0.000 claims description 8
- 210000000969 egg white Anatomy 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 238000011049 filling Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000005096 rolling process Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims 4
- 208000002193 Pain Diseases 0.000 abstract description 30
- 230000036407 pain Effects 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 21
- 210000004369 blood Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 11
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 238000010792 warming Methods 0.000 abstract description 7
- 230000003213 activating effect Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 description 71
- 208000024891 symptom Diseases 0.000 description 33
- 238000012360 testing method Methods 0.000 description 32
- 208000005171 Dysmenorrhea Diseases 0.000 description 20
- 230000027758 ovulation cycle Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 14
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 208000011580 syndromic disease Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 230000003821 menstrual periods Effects 0.000 description 7
- 230000005906 menstruation Effects 0.000 description 7
- 208000004998 Abdominal Pain Diseases 0.000 description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229960001680 ibuprofen Drugs 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 4
- 238000010832 independent-sample T-test Methods 0.000 description 4
- 206010042772 syncope Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 3
- 238000000546 chi-square test Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 206010000084 Abdominal pain lower Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 208000005641 Adenomyosis Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000758794 Asarum Species 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241001078983 Tetradium ruticarpum Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012854 evaluation process Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010831 paired-sample T-test Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H39/00—Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture
- A61H39/06—Devices for heating or cooling such points within cell-life limits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/235—Foeniculum (fennel)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/02—Characteristics of apparatus not provided for in the preceding codes heated or cooled
- A61H2201/0207—Characteristics of apparatus not provided for in the preceding codes heated or cooled heated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
- A61H2201/105—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy with means for delivering media, e.g. drugs or cosmetics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rehabilitation Therapy (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条,可有效解决寒凝血瘀型原发性痛经的治疗用药问题,该止痛药艾条是由柱状纸筒和药物两部分构成,所述的药物包括中药组合物和艾绒两部分,所述的中药组合物由以下中药原料:细辛、苏梗、白芷、檀香、玫瑰花、薰衣草、小茴香、吴茱萸、肉桂、干姜、当归、赤芍、延胡索、莪术、蒲黄、桑寄生制干,等重量混合均匀、粉碎制成;将中药组合物和艾绒的混合物装入纸筒内,并反复以木棒夯实,使艾绒松紧适宜,即成止痛药艾条。本发明原料丰富,制备方法简单,使用方便,具有温经通络、活血化瘀止痛的功效,有效用于治疗寒凝血瘀型原发性痛经,开辟了治疗寒凝血瘀型原发性痛经药物的新途径。
Description
技术领域
本发明涉及医药,特别是一种治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条。
背景技术
原发性痛经(PD)是指女性无盆腔脏器病变而出现的在经期或者经期前后腹部疼痛,其临床表现为女性在经期或行经前后出现小腹部的疼痛,常伴随有面色苍白、四肢无力、身重困倦、手足冰凉、恶心呕吐,甚至晕厥等,疼痛严重时可以放射至腰骶部,影响女性正常的生活工作和学习。艾灸法是艾叶燃烧之后产生的热量,作用于体表腧穴经络,给机体以温热刺激,从而起到温经散寒,通经活络的作用,可用来治疗冲任胞宫气血运行不畅引起的经行腹痛。原发性痛经是妇科常见病之一,近年来,妇女痛经现象有增多趋势,这类患者经受疾病的困扰,影响日常生活和工作。
传统清艾条灸虽然可以温经散寒,通经活络对原发性痛经有一定的治疗作用,但目前市面上艾条品质参差不齐,艾条成分单一,不能充分发挥中医辨证论治的诊疗特色,也无法达到对不同证型疾病的针对性治疗作用,因此研发专门治疗寒邪所导致痛经的药物,特别是用于治疗寒凝血瘀型原发性痛经的药灸条是需要认真解决的技术问题。
发明内容
针对上述情况,为克服现有技术之缺陷,本发明之目的就是提供一种治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条,可有效解决寒凝血瘀型原发性痛经的治疗用药问题。
本发明解决的技术方案是,一种治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条,该止痛药艾条是由柱状纸筒和药物两部分构成,所述的药物包括中药组合物和艾绒两部分,所述的中药组合物由以下中药原料:细辛、苏梗、白芷、檀香、玫瑰花、薰衣草、小茴香、吴茱萸、肉桂、干姜、当归、赤芍、延胡索、莪术、蒲黄、桑寄生制干,等重量混合均匀、粉碎制成;
所述的艾绒是由艾叶经过反复晒杵、捶打、粉碎,筛除杂质、粉尘,而得到的软细如棉的物品(公知技术);
中药组合物和艾绒的重量比为0.9-1.1︰5-7;
所述的柱状纸筒是桑皮纸卷成长度为18-22cm,直径1.8±0.2cm、2.8±0.2cm、3.8±0.2cm的柱状纸筒,用蛋清在纸筒表面涂抹均匀,再裹上一层桑皮纸,晾干,将中药组合物和艾绒的混合物装入纸筒内,并反复以木棒夯实,使艾绒松紧适宜,即成止痛药艾条。
本发明原料丰富,制备方法简单,使用方便,具有温经通络、活血化瘀止痛的功效,有效用于治疗寒凝血瘀型原发性痛经,开辟了治疗寒凝血瘀型原发性痛经药物的新途径,有显著的经济和社会效益。
具体实施方式
以下结合实施例和具体情况对本发明的具体实施方式作详细说明。
本发明在具体实施中可由以下实施例给出。
实施例1
本发明一种治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条,该止痛药艾条是由柱状纸筒和药物两部分构成,所述的药物包括中药组合物和艾绒两部分,所述的中药组合物由以下中药原料:细辛、苏梗、白芷、檀香、玫瑰花、薰衣草、小茴香、吴茱萸、肉桂、干姜、当归、赤芍、延胡索、莪术、蒲黄、桑寄生制干,等重量混合均匀、粉碎制成;
中药组合物和艾绒的重量比为1︰6;
所述的柱状纸筒是桑皮纸卷成长度为20cm,直径3cm的柱状纸筒,用蛋清在纸筒表面涂抹均匀,再裹上一层桑皮纸,晾干,将中药组合物和艾绒的混合物装入纸筒内,并反复以木棒夯实,使艾绒松紧适宜,即成止痛药艾条。
实施例2
本发明一种治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条,该止痛药艾条是由柱状纸筒和药物两部分构成,所述的药物包括中药组合物和艾绒两部分,所述的中药组合物由以下中药原料:细辛、苏梗、白芷、檀香、玫瑰花、薰衣草、小茴香、吴茱萸、肉桂、干姜、当归、赤芍、延胡索、莪术、蒲黄、桑寄生制干,等重量混合均匀、粉碎制成;
中药组合物和艾绒的重量比为0.9︰5.2;
所述的柱状纸筒是桑皮纸卷成长度为18cm,直径2cm的柱状纸筒,用蛋清在纸筒表面涂抹均匀,再裹上一层桑皮纸,晾干,将中药组合物和艾绒的混合物装满纸筒,并反复以木棒夯实,使艾绒松紧适宜,即成止痛药艾条。
实施例3
本发明一种治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条,该止痛药艾条是由柱状纸筒和药物两部分构成,所述的药物包括中药组合物和艾绒两部分,所述的中药组合物由以下中药原料:细辛、苏梗、白芷、檀香、玫瑰花、薰衣草、小茴香、吴茱萸、肉桂、干姜、当归、赤芍、延胡索、莪术、蒲黄、桑寄生制干,等重量混合均匀、粉碎制成;
中药组合物和艾绒的重量比为1.1︰6.8;
所述的柱状纸筒是桑皮纸卷成长度为22cm,直径4cm的柱状纸筒,用蛋清在纸筒表面涂抹均匀,再裹上一层桑皮纸,晾干,将中药组合物和艾绒的混合物装入纸筒内,并反复以木棒夯实,使艾绒松紧适宜,即成止痛药艾条。
要说明的是,各药物组分的用量是根据柱状纸筒容积的大小和数量来决定,可制成不同规格的系列药灸条。
在上述药物中,细辛解表散寒、祛风止痛;苏梗理气宽中止痛;白芷散风除湿、通窍止痛;小茴香散寒止痛;吴茱萸温中散寒;肉桂活血通经止痛;干姜温中散寒;当归补血活血;赤芍化瘀止痛;艾绒通经活络、温经止血、散寒止痛、养生保健,几种药物相配伍与艾绒混合灸治,可达到温经通络、活血化瘀止痛的功效,并经实验取得了非常好的有益技术效果,有关实验资料如下(以实施例1为例):
采用前瞻性随机对照的临床实验,2021年12月-2022年11月在河南中医药大学第三附属医院门诊收集患者74例,随机均分成试验组和对照组,试验组采用蠲邪止痛药艾条透灸神阙穴治疗,对照组采用西药布洛芬缓释胶囊治疗。以视觉模拟评分法(VAS)、中医症候积分、痛经症状评分、血清前列腺素F2α(PGF2α)、前列腺素E2(PGE2)含量为观察指标,对蠲邪止痛药艾条透灸神阙穴治疗寒凝血瘀型原发性痛经进行临床初步疗效评价,用Excel软件建立原始数据库,使用SPSS21.0统计软件包对收集的数据进行统计分析。
1.实验对象
本实验收集的病例均源于河南中药大学第三附属医院门诊2021年12月-2022年11月的患者。
2.病例选择标准
2.1西医诊断标准
参照2017年加拿大产科医师学会《原发性痛经临床指南》及《妇产科学》(第9版)中原发性痛经定义制定:
(1)临床表现:经期或月经来潮前后出现的周期性下腹部疼痛、坠胀,可有疲乏、腰骶部酸痛等其他伴随症状,甚则出现晕厥、休克等表现,严重影响正常生活;
(2)各项检查均未发现生殖器官器质性病变者。
2.2中医诊断标准
参照谈勇主编《中医妇科学》(第十版):
(1)中医痛经的诊断标准
女性在月经期间或经期前后反复出现下腹痛,或痛感放射至腰骶部,痛甚晕厥,即可诊断为痛经;
(2)痛经寒凝血瘀证型的辨证标准
主症:月经来潮时或月经前后小腹疼痛;
次症:①经量变少,②色暗有块,③肢冷畏寒,④面色青白;
舌脉:舌暗,苔白,脉沉紧;
主症必备,次症①~②症状中至少有一种,③~④症状中至少有一种,再通过舌脉诊断。
3筛选标准
3.1纳入标准
(1)符合西医、中医诊断标准者;
(2)年龄在16~30岁之间的未孕者;
(3)保证在治疗期间无性生活或有性生活而采取安全避孕措施者;
(4)月经周期规律,在28天±7天范围;
(5)3cm≤VAS<7cm;
(6)在接受此治疗之前,上一个月经周期没有接受过PD的相关治疗,且治疗前2周内未口服止痛药、激素药;
(7)理解并签署知情同意书
3.2排除标准
(1)哺乳期妇女、孕妇;
(2)VAS≥7cm;
(3)正在接受与PD相关治疗的患者;
(4)经由B超及妇科检查,证实痛经由子宫腺肌症、子宫肌瘤、子宫内膜异位症等引起且诊断为继发性痛经者;
(5)合并有严重的心、脑血管疾病、血液性疾病患者以及精神病患者;
(6)过敏性体质,对艾灸过敏者。
3.3中止标准
(1)在灸法治疗过程中出现严重的皮肤过敏反应或明显副作用;
(2)治疗过程中怀孕者;
(3)受试期间病情加重或出现并发症必须退出治疗者;
(4)纳入后由于各种原因不能继续配合治疗的患者。
3.4脱落标准
(1)主动放弃治疗者;
(2)多种原因导致失访者。
3.5剔除标准
(1)中途接受其他干预手段者;
(2)依从性较差,治疗记录和资料不完整者。
4.实验方案
4.1方案设计
(1)分组:采用SPSS21.0软件生成试验组和对照组的随机数字表,根据随机数字表在随机卡上标注随机数字及分组,然后将随机卡放入不透明信封中密封,并在信封上编号。患者根据就诊的时间顺序抽取信封,随机被分配到试验组或者对照组。
(2)盲法:考虑到药艾灸的特殊性,且对照组为布洛芬缓释胶囊组,无法对患者实施盲法操作,因此对研究人员设盲。命名随机数字序列的研究人员不可参与病例的收集及排除过程;录入试验数据的研究人员不可参与观察指标的评估过程;隐藏分组情况,两组别的名称不体现干预方法,以“组0”“组1”代称;对疗效评估的研究人员以及数据统计分析的研究人员设盲。
4.2样本量估算
根据试验设计方案,参考《医学统计方法学》中两独立样本率比较的样本量估计计算公式:
查阅相关文献可知布洛芬治疗PD的有效率74.80%,参考药艾条治疗PD的相关文献,预计蠲邪止痛药艾条透灸治疗寒凝血瘀型PD的有效率为93.33%,其中,q=1-p,分别代入公式计算得出每组样本量至少31例,两组至少62例,考虑到工作变动、疫情等可能导致样本脱落的因素,增加20%样本量,得出样本量约为74例,故最终计划纳入样本量74例进行研究。
4.3治疗方案
4.3.1试验组
(1)施灸材料:本发明蠲邪止痛药艾条;
(2)神阙穴:脐窝正中。(腧穴定位参照《针灸学》)
(3)具体操作:嘱受试者仰卧体位,充分暴露施术部位,并对该部位常规消毒。医生持长度约为20cm,直径为1.8±0.2cm的药艾条,用酒精灯将其一端点燃,然后将其放入特殊灸器中,将特殊灸器对准神阙穴部位放置固定,艾条距皮肤的距离约为1.5~3cm为宜,用特殊灸器布罩自上而下套在灸器底部,让布罩覆盖住整个腹部,治疗时间约为60min;
判断透灸成功的依据:患者体表反应及感受。施灸部位肤色潮红、伴有汗出,可能有红白相间的花斑出现;身体可出现局部肌肉的瞤动或沉重感、痒感、胀痛感等得气的感觉,或灸感向远端传导;
(4)疗程:治疗时间为经前3天至经行第2天,每日治疗1次,连续治疗5天。1个疗程以1个月经周期为单位计算,一共连续治疗3个疗程。
4.3.2对照组
(1)口服布洛芬缓释胶囊,每次0.3g,每日2次,早晚各1次(饭后)。(国药批号:H10900089;生产厂家:中美合资天津Smithkline制药有限公司;规格:0.3g×20粒。)
(2)疗程:于经前3天开始服药,直至经行第2天,连续治疗5天。1个疗程以1个月经周期为单位计算,一共连续治疗3个疗程。
5观察指标及时间
(1)一般临床资料:年龄、初潮年龄、痛经病史、月经周期。
(2)疗效性指标:
①VAS视觉模拟评分②中医证候积分②痛经症状积分
(3)实验室指标:血清PGE2、PGF2α含量检测
(4)观察时间:
分别在治疗前后收集受试者经行时的VAS、痛经症状评分、中医证候积分,并进行1个月经周期的随访,采集停止治疗后经行时的VAS、痛经症状评分、中医证候积分,以观察疗效的维持情况。
血清PGE2、PGF2α含量是在受试者未治疗时以及总治疗结束后的经行48h内取上肢静脉血,血液经过静置之后再离心,吸取血清,将之置于-20℃的环境中冷藏保存。血清样本收集完毕之后统一使用ELISA法检测,由江苏宝莱生物科技有限公司检测。
6疗效评价标准
根据《中药新药临床研究指导原则》疗效评价标准,参照痛经症状积分制定如下:
(1)痊愈:腹痛及伴随症状消失,得分降至0分;
(2)显效:腹部疼痛显著减轻,伴随症状改善,无需止痛药也能正常工作者,积分小于等于治疗前的1/2;
(3)有效:腹部疼痛得到改善,伴随症状也得到改善,口服止痛药后可以继续工作者,评分下降到治疗前的1/2~3/4(不包含1/2,包含3/4);
(4)无效:腹痛及其伴随症状无明显改善者,积分大于治疗前的3/4。
7数据收集与处理
收集2021年12月-2022年11月河南中医药大学第三附属医院门诊的寒凝血瘀型PD患者,评估患者,并采集相关信息,如姓名、入组日期、年龄、初潮年龄、病程、知情同意书、中医证候积分评定等。采集数据完毕,并双人双核后,统一将数据录至Excel表。
8统计学分析方法
采用SPSS21.0软件对采集的数据进行分析。若检测计量资料满足正态分布,则用均数±标准差表示,两组间的比较采用两独立样本t检验,组内的比较使用配对样本t检验。若经检测计量资料不满足正态分布,则用秩和检验,用M(P25,P75)表示,两组间的比较使用两独立样本秩和检验,两组内的比较使用配对样本秩和检验。二分类计数资料采用卡方检验,判据P<0.05,可以视为有统计学差异。
9.病例完成情况
本实验共收集74例病例,试验组2例未能按时治疗而脱落,对照组2例因在研究期间依从性差,漏服药而剔除,实际完成的病例是70例,其中试验组35例,对照组35例。(见表1)
表1病例实际完成情况
10.原始数据基线比较
10.1一般临床资料分析
试验组和对照组治疗前在年龄、初潮年龄、痛经病史、月经周期方面差异无统计学意义(P>0.05),具有可比性。(见表2)
表2对比两组治疗前年龄、初潮年龄、痛经病史、月经周期
注:两组患者治疗前年龄、初潮年龄、痛经病史、月经周期经正态性检验,符合正态分布,通过独立样本t检验,P>0.05,无统计学差异,可以进行对比。
10.2治疗前各项积分分析结果
表3对比两组治疗前各项积分
注:两组患者治疗前VAS、中医证候积分、痛经症状积分经过正态性检验之后,皆符合正态分布,通过独立样本t检验,P>0.05,没有统计学差异,具有可比性。
10.3治疗前实验室指标分析结果
表4对比两组治疗前PGE2、PGF2α
注:两组患者治疗前血清PGE2、PGF2α经正态性检验,符合正态分布,通过独立样本t检验,P>0.05,差异无统计学意义,具有可比性。
11治疗3个月经周期后各项结果分析
11.1治疗后两组组内各项评分比较
采用配对秩和检验分析,经过3个月经周期的治疗,两组治疗前后组内比较VAS、中医证候积分、痛经症状积分皆有显著下降,差异均具有极显著统计学意义(P<0.001)。(见表5、表6)表5试验组治疗前后组内各项分析比较
表6对照组治疗前后组内各项积分分析比较
11.2治疗后两组组内PGE2、PGF2α含量比较
采用配对秩和检验分析,经过3个月经周期的治疗,试验组和对照组在治疗后与治疗前组内对比血清PGE2含量均明显升高、PGF2α含量均明显下降,差异均具有极显著统计学意义(P<0.001)。(见表7、表8)
表7试验组治疗前后组内PGE2、PGF2α分析比较
表8对照组治疗前后组内PGE2、PGF2α分析比较
11.3治疗后两组组间各项评分比较
采用独立样本秩和检验分析,经过3个月经周期的治疗,试验组和对照组组间对比VAS、中医证候积分、痛经症状积分变化均没有统计学差异(P>0.05)。(见表9)
表9对比两组治疗后组间各项积分
11.4治疗后两组组间PGE2、PGF2α含量比较
采用独立样本秩和检验分析,经过3个月经周期的治疗,试验组和对照组组间对比血清PGE2、PGF2α含量差异均无统计学意义(P>0.05)。(见表10)
表10对比两组治疗后组间PGE2、PGF2α
12.随访各项结果分析
停止治疗1个月之后,随访两组受试者,采用独立样本秩和检验分析,试验组和对照组组间对比VAS、中医证候积分、痛经症状积分变化差异均具有统计学意义(P<0.05)。(见表11)
表11对比两组治疗后随访期各项积分
13.临床疗效对比
13.1临床疗效对比
3个月治疗结束后,试验组的临床总有效率为91.4%,对照组临床总有效率为88.6%,用连续校正的卡方检验对比两组之间的临床总有效率,差异没有统计学意义(P>0.05)。(见表12)
表12两组临床疗效对比
13.2随访期临床疗效对比
停止治疗1个月后,对两组受试者进行随访,试验组随访期临床总有效率为85.7%,对照组随访期临床总有效率为42.9%,用卡方检验对比两组间总有效率,差异具有极显著统计学意义(P<0.001)。(见表13)
表13两组随访期临床疗效对比
14.不良反应与评价
在本实验的整个过程中,试验组均未出现烧烫伤、咳嗽、头晕等不良反应;对照组有1名患者因空腹服用本研究的指定药物而出现轻微的腹痛。随即叮嘱患者不可再空腹服药,遂未出现药后不良反应。试验组和对照组所有受试者均未出现气短、胸闷、呼吸不畅、晕厥等副作用,用药安全。
15.结论
15.1基线资料比较:治疗前两组患者的基线资料在年龄、初潮年龄、痛经病史、月经周期方面没有统计学差异(P>0.05),可进行对比。
15.2VAS:两组经治疗之后VAS评分均显著下降,且二者治疗前后的组内对比均有极显著差异(P<0.001),治疗后两组之间对比差异没有统计学意义(P>0.05)。随访时,两组之间对比差异有统计学意义(P<0.05),试验组的改善情况优于对照组。
15.3中医证候积分:治疗结束后,两组中医证候积分均显著下降,组内对比有极显著差异(P<0.001),两组之间对比差异没有统计学意义(P>0.05)。随访时,组间对比差异有统计学意义(P<0.05),试验组低于对照组。
15.4痛经症状积分:治疗结束之后,两组的痛经症状积分呈现显著下降趋势,与治疗前进行组内对比有极显著差异(P<0.001),治疗后的组间对比差异无统计学意义(P>0.05)。随访时,组间对比差异有统计学意义(P<0.05),试验组积分低于对照组。
15.5血清PGE2、PGF2α含量:治疗后,两组皆能使血清PGE2水平升高,使PGF2α水平下降,治疗前后组内对比有极显著差异(P<0.001),组间对比差异没有统计学意义(P>0.05)。
15.6临床有效率:试验组临床总有效率为91.4%,对照组为88.6%;试验组远期临床总有效率为85.7%,对照组为42.9%,有极显著的差异(统计学意义P<0.001)。
蠲邪止痛药艾条透灸与布洛芬缓释胶囊均能明显改善寒凝血瘀型原发性痛经患者的主要症状及伴随症状,并能调节前列腺素的水平。
蠲邪止痛药艾条透灸与布洛芬缓释胶囊治疗寒凝血瘀型原发性痛经虽然近期疗效不相上下,但前者远期疗效明显优于后者,且前者为外治法,安全系数高,无副作用,更值得临床推广。
在上述对实施例1做实验的同时,还对其它实施例作了相同实验,均取得了相同或相近似的技术效果,这里不再一一列举。
综上,本发明原料丰富,制备方法简单,使用方便,具有温经通络、活血化瘀止痛的功效,有效用于治疗寒凝血瘀型原发性痛经,施药安全,疗效好,疗效高达91.4%,开辟了治疗寒凝血瘀型原发性痛经药物的新途径,有显著的经济和社会效益。
Claims (4)
1.一种治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条,其特征在于,该止痛药艾条是由柱状纸筒和药物两部分构成,所述的药物包括中药组合物和艾绒两部分,所述的中药组合物由以下中药原料:细辛、苏梗、白芷、檀香、玫瑰花、薰衣草、小茴香、吴茱萸、肉桂、干姜、当归、赤芍、延胡索、莪术、蒲黄、桑寄生制干,将各中药原料等重量混合均匀、粉碎制成;
中药组合物和艾绒的重量比为0.9-1.1︰5-7;
所述的柱状纸筒是桑皮纸卷成长度为18-22cm,直径1.8±0.2cm、2.8±0.2cm、3.8±0.2cm的柱状纸筒,用蛋清在纸筒表面涂抹均匀,再裹上一层桑皮纸,晾干,将中药组合物和艾绒的混合物装入纸筒内,并反复以木棒夯实,使艾绒松紧适宜,即成止痛药艾条。
2.根据权利要求1所述的治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条,其特征在于,该止痛药艾条是由柱状纸筒和药物两部分构成,所述的药物包括中药组合物和艾绒两部分,所述的中药组合物由以下中药原料:细辛、苏梗、白芷、檀香、玫瑰花、薰衣草、小茴香、吴茱萸、肉桂、干姜、当归、赤芍、延胡索、莪术、蒲黄、桑寄生制干,将各中药原料等重量混合均匀、粉碎制成;
中药组合物和艾绒的重量比为1︰6;
所述的柱状纸筒是桑皮纸卷成长度为20cm,直径3cm的柱状纸筒,用蛋清在纸筒表面涂抹均匀,再裹上一层桑皮纸,晾干,将中药组合物和艾绒的混合物装入纸筒内,并反复以木棒夯实,使艾绒松紧适宜,即成止痛药艾条。
3.根据权利要求1所述的治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条,其特征在于,该止痛药艾条是由柱状纸筒和药物两部分构成,所述的药物包括中药组合物和艾绒两部分,所述的中药组合物由以下中药原料:细辛、苏梗、白芷、檀香、玫瑰花、薰衣草、小茴香、吴茱萸、肉桂、干姜、当归、赤芍、延胡索、莪术、蒲黄、桑寄生制干,将各中药原料等重量混合均匀、粉碎制成;
中药组合物和艾绒的重量比为0.9︰5.2;
所述的柱状纸筒是桑皮纸卷成长度为18cm,直径2cm的柱状纸筒,用蛋清在纸筒表面涂抹均匀,再裹上一层桑皮纸,晾干,将中药组合物和艾绒的混合物装满纸筒,并反复以木棒夯实,使艾绒松紧适宜,即成止痛药艾条。
4.根据权利要求1所述的治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条,其特征在于,该止痛药艾条是由柱状纸筒和药物两部分构成,所述的药物包括中药组合物和艾绒两部分,所述的中药组合物由以下中药原料:细辛、苏梗、白芷、檀香、玫瑰花、薰衣草、小茴香、吴茱萸、肉桂、干姜、当归、赤芍、延胡索、莪术、蒲黄、桑寄生制干,将各中药原料等重量混合均匀、粉碎制成;
中药组合物和艾绒的重量比为1.1︰6.8;
所述的柱状纸筒是桑皮纸卷成长度为22cm,直径4cm的柱状纸筒,用蛋清在纸筒表面涂抹均匀,再裹上一层桑皮纸,晾干,将中药组合物和艾绒的混合物装入纸筒内,并反复以木棒夯实,使艾绒松紧适宜,即成止痛药艾条。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310496722.XA CN116650611B (zh) | 2023-05-05 | 2023-05-05 | 一种治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310496722.XA CN116650611B (zh) | 2023-05-05 | 2023-05-05 | 一种治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116650611A CN116650611A (zh) | 2023-08-29 |
CN116650611B true CN116650611B (zh) | 2024-05-17 |
Family
ID=87719750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310496722.XA Active CN116650611B (zh) | 2023-05-05 | 2023-05-05 | 一种治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116650611B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105214048A (zh) * | 2015-10-30 | 2016-01-06 | 青岛申达高新技术开发有限公司 | 用于治疗寒凝血瘀型原发性痛经的药物 |
CN111714610A (zh) * | 2020-07-14 | 2020-09-29 | 广西中医药大学赛恩斯新医药学院 | 用于治疗寒凝血瘀型痛经的中药组合物及其制备方法 |
-
2023
- 2023-05-05 CN CN202310496722.XA patent/CN116650611B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105214048A (zh) * | 2015-10-30 | 2016-01-06 | 青岛申达高新技术开发有限公司 | 用于治疗寒凝血瘀型原发性痛经的药物 |
CN111714610A (zh) * | 2020-07-14 | 2020-09-29 | 广西中医药大学赛恩斯新医药学院 | 用于治疗寒凝血瘀型痛经的中药组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
温经化瘀止痛方联合艾灸治疗原发性痛经疗效观察;张彦;袁海光;;四川中医;20171115(第11期);169-171 * |
Also Published As
Publication number | Publication date |
---|---|
CN116650611A (zh) | 2023-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1061854C (zh) | 治疗、预防妇科疾患的药物制剂 | |
CN101804174B (zh) | 治疗干燥综合征的中药制剂 | |
CN100584354C (zh) | 一种治疗带状疱疹后遗神经痛的药物 | |
CN101274024B (zh) | 一种治疗牙疼的药物组合物 | |
CN112022916A (zh) | 一种治疗产后身痛中药组合物、制剂及其制备方法和应用 | |
CN104435519A (zh) | 一种治疗原发性痛经的药物组合物 | |
CN116650611B (zh) | 一种治疗寒凝血瘀型原发性痛经的蠲邪止痛药艾条 | |
CN103285284B (zh) | 一种治疗老年性阴道炎的药物组合物 | |
CN102688434B (zh) | 一种治疗糖尿病的中药 | |
CN102258696B (zh) | 治疗未分化脊柱关节炎的复方中药及应用 | |
CN1895357A (zh) | 一种治疗肾阴阳两虚的中药 | |
CN112826915A (zh) | 一种治疗痛经的中药组合物及制剂和制备方法 | |
CN1915400A (zh) | 治疗鼻渊病症的药物 | |
CN109091570A (zh) | 一种治疗硬皮病的中药 | |
TWI840312B (zh) | 一種中藥組合物及其用途 | |
CN115837065B (zh) | 一种中药组合物及其用途 | |
CN115804805B (zh) | 一种治疗强直性脊柱炎的中药复方组合物及外用药包 | |
CN102961662B (zh) | 一种治疗胃溃疡的药物及其制备方法 | |
CN106266970B (zh) | 一种治疗生产引发子宫内膜炎的中药组合物 | |
CN102205047B (zh) | 一种治疗强直性脊柱炎的中药组合物 | |
CN110090271B (zh) | 一种治疗男性不育症的中药组合物、制剂及其应用 | |
CN1076622C (zh) | 一种治疗肾炎的中药 | |
CN105663343A (zh) | 治疗妇科慢性盆腔炎的中药复方制剂 | |
Fan et al. | Clinical Application of Acupoint Application Therapy in Pediatrics | |
CN104189870A (zh) | 一种治疗过敏性哮喘的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |